Novel Pancreatic Cancer Drug Daraxonrasib Shows Unprecedented Survival Gains in Early Data
Daraxonrasib targets RAS mutations in pancreatic cancer, showing 35% response rates and 13-month survival — far outpacing current chemo options.
Summary
Daraxonrasib, an investigational drug targeting RAS G12 mutations, is showing remarkable results against pancreatic ductal adenocarcinoma — one of the deadliest cancers. In a phase I/II trial published in the New England Journal of Medicine, patients receiving the 300mg dose achieved a 35% response rate and 92% disease control rate in second-line treatment, with median overall survival of 13.1 months. This compares dramatically to current chemotherapy, which yields response rates below 10% and median survival of 5–7 months. The FDA has now allowed an expanded access program, and a phase III trial reportedly showed 'unprecedented' overall survival improvement. Side effects including rash, diarrhea, and nausea were common, with serious grade 3+ events in 30% of patients.
Detailed Summary
Pancreatic cancer remains one of the most lethal malignancies, with few effective treatment options beyond first-line chemotherapy. The emergence of daraxonrasib, a RAS(ON) inhibitor targeting the RAS G12 mutation, represents a potentially transformative shift in how this disease is treated — and the latest data suggest the excitement is warranted.
In a phase I/II trial led by researchers at Dana-Farber Cancer Institute and published in the New England Journal of Medicine, patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) receiving 300mg of daraxonrasib achieved a 35% response rate and a 92% disease control rate. Median progression-free survival reached 8.5 months and overall survival hit 13.1 months — numbers that dwarf current second-line chemotherapy benchmarks of under 10% response rates and 5–7 months median survival.
The safety profile showed treatment-related adverse events in nearly all patients, most commonly rash, diarrhea, and nausea. Roughly 30% experienced grade 3 or higher events, which is clinically significant but considered manageable in the context of a disease with so few alternatives. Discontinuation due to disease progression in over half of patients underscores that resistance mechanisms remain a critical challenge.
The FDA recently authorized an expanded access program for daraxonrasib, and Revolution Medicines — the drug's developer — announced 'unprecedented' overall survival results from the ongoing phase III RASolute 302 trial. Separately, two studies presented at the American Association for Cancer Research meeting showed response rates of 50–60% in previously untreated patients, suggesting even greater potential earlier in the disease course.
Experts emphasize that identifying predictive biomarkers and designing combination strategies to overcome resistance will be essential next steps. For patients with RAS-mutant pancreatic cancer and their clinicians, the expanded access program now offers a meaningful new option while phase III data matures.
Key Findings
- Daraxonrasib achieved 35% response rate and 92% disease control in previously treated RAS G12-mutant pancreatic cancer patients
- Median overall survival of 13.1 months far exceeds current second-line chemo benchmark of 5–7 months
- FDA authorized expanded access program, making daraxonrasib available now through licensed prescribers
- Grade 3+ treatment-related adverse events occurred in 30% of patients; rash, diarrhea, and nausea were most common
- Early-line studies suggest 50–60% response rates, hinting at even stronger benefit before prior treatment
Methodology
This is a news report summarizing a phase I/II clinical trial published in the New England Journal of Medicine, a top-tier peer-reviewed journal. The source, MedPage Today, is a credible medical journalism outlet targeting clinicians. Evidence is based on prospective trial data with defined endpoints including response rate, PFS, and OS.
Study Limitations
Phase I/II data has inherent limitations including smaller sample sizes and lack of randomized controls; full phase III results have not yet been published. The 'unprecedented' survival claim from Revolution Medicines is company-announced and not yet peer-reviewed. Long-term safety and resistance mechanisms remain incompletely characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.